Doing the Work

Client medications:What we ask and what we say

Many people come to psilocybin services hoping for help with depression or anxiety, which means many of them are also taking an antidepressant. If they've read much about it, they've probably seen that selective serotonin reuptake inhibitors (SSRIs) can blunt the experience, and that people in clinical trials stopped their medications first. So they ask us, "Do I need to stop my antidepressant before this?" A facilitator can't answer that with anything more than "that's a question for your prescriber." We do talk with people about their medications, because they can shape what's possible in a session, but our part is screening and explanation: asking what someone takes, recognizing when a medication raises a safety concern, and describing how it might affect a journey. Doing that well means knowing exactly where our knowledge, and our authority, stops.

What we ask about, and why

The conversation usually starts with paperwork. In Oregon, every client fills out a state client information form with a facilitator before an administration session. In Colorado, facilitators are required to run a safety screen with each participant. We treat whatever the client wrote down as a first draft. People forget the pill they take only before flying, leave off supplements, or list a medication they stopped last month. So we go through it together and ask about what isn't there: anything taken now and then, anything that changed recently, and cannabis, alcohol, or other substances.

Lithium is one named drug that stops us and both states require action, if slightly differently in each. In 2021, a team at Johns Hopkins looked at online reports from people who had combined a classic psychedelic like psilocybin or LSD with a mood stabilizer. Of 62 reports involving lithium, almost half described a seizure, and more than a third involved medical attention. None of the 34 reports involving lamotrigine, another mood stabilizer, described a seizure. The researchers called their conclusion provisional, but the pattern is strong. Oregon's client information form asks by name whether the client has taken lithium in the last 30 days, and anyone who answers yes can't take part in an administration session. In Colorado, a facilitator can't provide services to someone taking lithium or an antipsychotic unless that person has a referral from a medical or behavioral health provider, medical clearance from their own provider, or a consultation and risk review with a provider licensed to treat their condition. Many newer antipsychotics also block the serotonin receptors psilocybin acts on, so the journey may be muted or barely there.

SSRIs and their close relatives, the serotonin-norepinephrine reuptake inhibitors (SNRIs), prompt most of the questions, and the honest answer is that the picture is mixed. Plenty of people say their journeys felt weaker on an SSRI, and trial designers worried enough that stopping antidepressants became a standard condition of joining a psilocybin study. For us, an SSRI usually leads to a conversation about expectations, and it's rarely a reason to pause. Others come up too. Monoamine oxidase inhibitors (MAOIs) can intensify and lengthen a psychedelic experience, psilocybin raises heart rate and blood pressure for a few hours, which brings blood pressure medications into the conversation, and a benzodiazepine taken the morning of a session "just in case" can soften the experience.

Where our authority stops

Neither Oregon nor Colorado allows facilitators to diagnose or treat medical or mental health conditions. Telling someone to stop, lower, or keep taking a prescription is treatment advice, even when it's offered casually in a preparation session. It's also advice we're in no position to give. We don't know why the medication was prescribed, what happened the last time the person came off it, or how fast it can safely be reduced. Their prescriber does. Getting it wrong has costs. Stopping an antidepressant abruptly can bring on discontinuation symptoms such as dizziness, irritability, poor sleep, and the brief electrical sensations many people call brain zaps. For someone whose medication has been keeping a serious depression in check, stopping can lead to relapse, sometimes weeks later.

People often bring up the trials. Participants who came off antidepressants did it under medical supervision, on a planned schedule, partly so other drugs wouldn't muddy the results. It was a design decision for a study, never advice for someone booking a session. The research has also moved on. In a 2023 study, 19 adults with treatment-resistant depression who stayed on their SSRIs took a single 25 mg dose of a psilocybin formulation called COMP360. They still reported strong effects, and their depression scores dropped over the following three weeks, though the study had no comparison group and can't say how much of that came from psilocybin. In a controlled study of healthy volunteers published in 2022, two weeks of escitalopram didn't change the positive mood effects of a 25 mg dose, though it did reduce anxiety and other unpleasant effects. Together they cut against the idea that being on an SSRI makes psilocybin pointless.

What we can do is still substantial. We can explain what's known and unknown about someone's medication and psilocybin, help them prepare questions for their prescriber, write a short description of what services involve for that prescriber, and decline or postpone when a medication makes a session unsafe.

Leah's question

Leah was fifty-two and had been on sertraline for eight years. In her first preparation session she asked almost right away whether she should stop it for a few weeks, because she'd read she would "barely feel anything." Her facilitator told her she couldn't advise changing a prescription, explained why, and then told Leah what she did know: some people on SSRIs describe a milder journey, some describe one that feels complete, and the one study of people who stayed on their SSRIs found they still reported strong effects. Leah asked whether a milder session would mean she'd wasted her money. Her facilitator asked what she wanted from a session that turned out quieter than she expected, and Leah said she wanted a few hours to think about her mother without being interrupted, which she might get either way.

Leah took the question to her prescriber with a one-page description of the session her facilitator wrote, and her prescriber advised her to stay on the sertraline. Going back over her intake, Leah also remembered a lorazepam prescription she used only before flying, and they agreed she wouldn't take it on the day of her session. Afterward she described her journey as "gentler than I expected and longer than I expected," and she spent much of it thinking about her mother.

The same conversation goes differently when the risk is serious. Another client mentioned in passing that he'd gone back on lithium that winter, after filling out his form. His facilitator explained the seizure reports, told him she couldn't go ahead while he was taking it, and made clear she wasn't advising him to stop. In both cases the skill looks less like expertise in pharmacology and more like thoroughness and restraint: asking the follow-up questions that catch what the form missed, knowing which answers mean stopping, and saying plainly which questions belong to someone else.


Editor's note. Leah and the second client are composites drawn from common situations in preparation, with details changed. Sources, accessed November 17, 2026: Nayak et al., "Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures," Pharmacopsychiatry, 2021; Goodwin et al., "Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication," Neuropsychopharmacology, 2023; Becker et al., "Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects," Clinical Pharmacology & Therapeutics, 2022; Oregon Administrative Rules chapter 333, division 333 (client information form and the lithium question; facilitators may not diagnose or treat); Colorado rules 4 CCR 755-1, Rule 2.2 (facilitator scope; lithium and antipsychotic medications; referral, clearance, or consultation and risk review).

← All posts